Patrick Arensdorf

Pat brings more than 20 years of leadership experience as a healthcare entrepreneur to his role as co-founder and CEO of Exai. He previously served as an Entrepreneur-in-Residence at the University of California, San Francisco Innovation Ventures. Prior to Exai and UCSF, Pat was co-founder and CEO for Bluestar Genomics, CEO for Critical Diagnostics, and a member of the founding management teams at Tethys Bioscience (acquired by HDL) and Intersect ENT (acquired by Medtronic). Pat began his career as a financial advisor and strategy consultant in the private equity industry, entering the diagnostic field as the turnaround CEO for First Medical (acquired by Sigma-Aldrich). He has a master’s degree in management from the Stanford Graduate School of Business and a bachelor's degree in molecular biology from Princeton University.